Article
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Acta neuropathologica - 1 Dec 2013
Remke Marc, Ramaswamy Vijay, Peacock John, Shih David J H, Koelsche Christian, Northcott Paul A, Hill Nadia, Cavalli Florence M G, Kool Marcel, Wang Xin, Mack Stephen C, Barszczyk Mark, Morrissy A Sorana, Wu Xiaochong, Agnihotri Sameer, Luu Betty, Jones David T W, Garzia Livia, Dubuc Adrian M, Zhukova Nataliya, Vanner Robert, Kros Johan M, French Pim J, Van Meir Erwin G, Vibhakar Rajeev, Zitterbart Karel, Chan Jennifer A, Bognár László, Klekner Almos, Lach Boleslaw, Jung Shin, Saad Ali G, Liau Linda M, Albrecht Steffen, Zollo Massimo, Cooper Michael K, Thompson Reid C, Delattre Oliver O, Bourdeaut Franck, Doz François F, Garami Miklós, Hauser Peter, Carlotti Carlos G, Van Meter Timothy E, Massimi Luca, Fults Daniel, Pomeroy Scott L, Kumabe Toshiro, Ra Young Shin, Leonard Jeffrey R, Elbabaa Samer K, Mora Jaume, Rubin Joshua B, Cho Yoon-Jae, McLendon Roger E, Bigner Darell D, Eberhart Charles G, Fouladi Maryam, Wechsler-Reya Robert J, Faria Claudia C, Croul Sidney E, Huang Annie, Bouffet Eric, Hawkins Cynthia E, Dirks Peter B, Weiss William A, Schüller Ulrich, Pollack Ian F, Rutkowski Stefan, Meyronet David, Jouvet Anne, Fèvre-Montange Michelle, Jabado Nada, Perek-Polnik Marta, Grajkowska Wieslawa A, Kim Seung-Ki, Rutka James T, Malkin David, Tabori Uri, Pfister Stefan M, Korshunov Andrey, von Deimling Andreas, Taylor Michael D
Abstract excerpt
Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing...
Read the complete abstract on PubMed